Last Updated:
Searching
Create account to add to watchlist!
Create account to add to watchlist!

Eucrates Biomedical Acquisition Corp. - EUCR

  • Commons

    $10.02

    -0.10%

    EUCR Vol: 17.0K

  • Warrants

    $0.03

    +0.00%

    EUCRW Vol: 0.0

  • Units

    $10.02

    +0.30%

    EUCRU Vol: 2.8K

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 134.6M
Average Volume: 31.4K
52W Range: $9.75 - $10.74
Weekly %: +0.00%
Monthly %: +0.21%
Inst Owners: 48

Info

Target: Searching
Days Since IPO: 710
Unit composition:
Each unit consists of one ordinary share and one-third of one warrant, which we refer to throughout this prospectus as β€œwarrants” or the β€œpublic warrants.” Each whole warrant entitles the holder thereof to purchase one ordinary share at a price of $11.50 per share, subject to adjustment as described
Trust Size: 10000000.0M

πŸ•΅Stocktwit Mentions

cctranscripts posted at 2022-09-28T21:52:27Z

Other preliminary proxy statements https://www.conferencecalltranscripts.com/summary/?id=11341655 $EUCR

risenhoover posted at 2022-09-28T21:31:41Z

$EUCR / Eucrates Biomedical Acquisition files form PRE 14A https://fintel.io/sf/us/eucr?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2022-09-28T21:31:33Z

$EUCR πŸ“œ SEC Form PRE 14A filed by Eucrates Biomedical Acquisition Corp. https://quantisnow.com/i/3468203?utm_source=stocktwits 45 seconds delayed.

Newsfilter posted at 2022-09-28T21:30:42Z

$EUCR Form PRE 14A (other preliminary proxy statements) filed with the SEC https://newsfilter.io/a/1b22af550b59351212936c99355801f7

bigwhalealert posted at 2022-08-25T18:06:00Z

$EUCR BUY/SELL METER Alert Cross 31% +- Technical Analysis https://t8sk.com/EUCR

Last10K posted at 2022-08-16T00:11:32Z

$EUCR just filed a 10-Q Quarterly Report with 5 financial statements and 29 disclosures. Access them all or just read their earnings: https://last10k.com/sec-filings/eucr/0001410578-22-002601.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=eucr

stockilluminati posted at 2022-08-15T21:31:19Z

$EUCR https://www.stockilluminati.com/eucr/filings.php - Eucrates Biomedical Acquisition Corp. - Ordinary Shares files form 10-Q today, check out the details.

Quantisnow posted at 2022-08-15T21:13:12Z

$EUCR πŸ“œ SEC Form 10-Q filed by Eucrates Biomedical Acquisition Corp. https://quantisnow.com/i/3289592?utm_source=stocktwits 45 seconds delayed.

Newsfilter posted at 2022-08-15T21:12:22Z

$EUCR Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/3e8171f3f9fed6cc4dc520731448b368

ChartMill posted at 2022-06-06T01:43:00Z

$EUCR shows a strong growth in EPS: 2828.57%. https://www.chartmill.com/stock/quote/EUCR/fundamental-analysis?key=e29ffdab-4657-4ea7-bb4d-81e89518daac&utm_source=stocktwits&utm_medium=FA&utm_content=EUCR&utm_campaign=social_tracking

cctranscripts posted at 2022-05-23T20:48:25Z

Eucrates Biomedical Acquisition Corp. Just Filed Its Quarterly Report: Net Income Per Share... https://www.conferencecalltranscripts.com/summary/?id=10885233 $EUCR

Last10K posted at 2022-05-23T20:39:29Z

$EUCR just filed a 10-Q Quarterly Report with 36 sections and 4 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/eucr/0001410578-22-001827.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=eucr

risenhoover posted at 2022-05-23T20:34:06Z

$EUCR / Eucrates Biomedical Acquisition files form 10-Q https://fintel.io/sf/us/eucr?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2022-05-23T20:33:32Z

$EUCR πŸ“œ SEC Form 10-Q filed by Eucrates Biomedical Acquisition Corp. https://quantisnow.com/i/2930249?utm_source=stocktwits 45 seconds delayed. Real-time feed at πŸš† https://quantisnow.com/feed πŸš†

Newsfilter posted at 2022-05-23T20:32:47Z

$EUCR Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/283da9f639f2d73c0a94fc1c75f9e78b

risenhoover posted at 2022-05-16T22:19:35Z

$EUCR / Eucrates Biomedical Acquisition files form NT 10-Q https://fintel.io/sf/us/eucr?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

cctranscripts posted at 2022-05-16T21:03:17Z

Notification of inability to timely file Form 10-Q or 10-QSB https://www.conferencecalltranscripts.com/summary/?id=10857235 $EUCR

Quantisnow posted at 2022-05-16T20:51:21Z

$EUCR πŸ“œ SEC Form NT 10-Q filed by Eucrates Biomedical Acquisition Corp. https://quantisnow.com/i/2896687?utm_source=stocktwits 45 seconds delayed.

Newsfilter posted at 2022-05-16T20:50:33Z

$EUCR Form NT 10-Q (notification of inability to timely file form 10-q or 10-qsb) filed with the SEC https://newsfilter.io/a/743cf903ca941c7c718d1c3e8379bbc4

Fullratio posted at 2022-04-12T16:12:33Z

$EUCR total liabilities has decreased by 44% YoY and by 7% QoQ: https://fullratio.com/stocks/nasdaq-eucr/eucrates-biomedical-acquisition

Last10K posted at 2022-04-11T10:08:28Z

$EUCR just filed a 10-K Annual Report with 38 sections and 4 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/eucr/0001410578-22-000855.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=eucr

cctranscripts posted at 2022-04-11T10:07:36Z

Eucrates Biomedical Acquisition Corp. Just Filed Its Annual Report: Net Income (Loss) Pe... https://www.conferencecalltranscripts.com/summary/?id=10693778 $EUCR

risenhoover posted at 2022-04-11T10:04:56Z

$EUCR / Eucrates Biomedical Acquisition files form 10-K https://fintel.io/sf/us/eucr?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2022-04-11T10:04:47Z

$EUCR πŸ“œ SEC Form 10-K filed by Eucrates Biomedical Acquisition Corp. https://quantisnow.com/i/2701815?utm_source=stocktwits 45 seconds delayed.

Quantisnow posted at 2022-03-31T21:15:35Z

$EUCR πŸ“œ SEC Form NT 10-K filed by Eucrates Biomedical Acquisition Corp. https://quantisnow.com/i/2660435?utm_source=stocktwits 45 seconds delayed.

Newsfilter posted at 2022-03-31T21:14:48Z

$EUCR Form NT 10-K (notification of inability to timely file form 10-k 405, 10-k, 10-ksb 405, 10-ksb, 10-kt, or 10-kt405) filed with the SEC https://newsfilter.io/a/2ac95f8483174908d74ea3a80d60f732

cctranscripts posted at 2022-02-14T22:07:30Z

T. ROWE PRICE ASSOCIATES, INC. just provided an update on share ownership of Eucrates Biomedica https://www.conferencecalltranscripts.com/summary/?id=10445538 $EUCR

Quantisnow posted at 2022-02-14T19:43:39Z

$EUCR πŸ“œ SEC Form SC 13G filed by Eucrates Biomedical Acquisition Corp. https://quantisnow.com/insight/2410868?s=s 45 seconds delayed.

Newsfilter posted at 2022-02-14T19:42:54Z

$EUCR Form SC 13G (statement of acquisition of beneficial ownership by individuals) filed with the SEC https://newsfilter.io/a/94847af18796d92933c162555fa540b8

cctranscripts posted at 2022-02-08T23:39:27Z

BlackRock, Inc. just provided an update on share ownership of Eucrates Biomedical Acquisition C https://www.conferencecalltranscripts.com/summary/?id=10411849 $EUCR

Management

Officers and Directors Our memorandum and articles of association provide that, subject to certain limitations, the company shall indemnify its directors and officers against all expenses, including legal fees, and against all judgments, fines and amounts paid in settlement and reasonably incurred in connection with legal, administrative or investigative proceedings. Such indemnity only applies if the person acted honestly and in good faith with a view to the best interests of the company and, in the case of criminal proceedings, the person had no reasonable cause to believe that their conduct was unlawful. The decision of the directors as to whether the person acted honestly and in good faith and with a view to the best interests of the company and as to whether the person had no reasonable cause to believe that his conduct was unlawful and is, in the absence of fraud, sufficient for the purposes of the memorandum and articles of association, unless a question of law is involved. The termination of any proceedings by any judgment, order, settlement, conviction or the entering of a nolle prosequi does not, by itself, create a presumption that the person did not act honestly and in good faith and with a view to the best interests of the company or that the person had reasonable cause to believe that his conduct was unlawful. We will enter into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our memorandum and articles of association. Our memorandum and articles of association also will permit us to purchase and maintain insurance on behalf of any officer or director who at the request of the Company is or was serving as a director or officer of, or in any other capacity is or was acting for, another company or a partnership, joint venture, trust or other enterprise, against any liability asserted against the person and incurred by the person in that capacity, whether or not the company has or would have had the power to indemnify the person against the liability as provided in the memorandum and articles of association. We will purchase a policy of directors’ and officers’ liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. These provisions may discourage shareholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions. We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable. 110 TABLE OF CONTENTS​ PRINCIPAL SHAREHOLDERS The following table sets forth information regarding the beneficial ownership of our ordinary shares as of the date of this prospectus, and as adjusted to reflect the sale of our ordinary shares included in the units offered by this prospectus and private units, and assuming no purchase of units in this offering, by: β€’ each person known by us to be the beneficial owner of more than 5% of our outstanding ordinary shares; ​ β€’ each of our officers, directors and director nominees that beneficially owns ordinary shares; and ​ β€’ all our officers and directors as a group. ​ Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all ordinary shares beneficially owned by them. The following table does not reflect record or beneficial ownership of any ordinary shares issuable upon exercise of warrants as these warrants are not exercisable within 60 days of the date of this prospectus. ​ ​ ​ Prior to Offering ​ ​ After Offering(2) ​ Name and Address of Beneficial Owner(1) ​ ​ Amount and Nature of Beneficial Ownership ​ ​ Approximate Percentage of Outstanding Ordinary Shares(3) ​ ​ Amount and Nature of Beneficial Ownership ​ ​ Approximate Percentage of Outstanding Ordinary Shares(4) ​ Eucrates LLC(5) ​ ​ ​ ​ 2,875,000 ​ ​ ​ ​ ​ 100.0% ​ ​ ​ ​ ​ 2,850,000 ​ ​ ​ ​ ​ 22.2% ​ ​ Dr. Stelios Papadopoulos(5) ​ ​ ​ ​ 2,875,000 ​ ​ ​ ​ ​ 100.0% ​ ​ ​ ​ ​ 2,850,000 ​ ​ ​ ​ ​ 22.2% ​ ​ Parag Saxena(5) ​ ​ ​ ​ 2,875,000 ​ ​ ​ ​ ​ 100.0% ​ ​ ​ ​ ​ 2,850,000 ​ ​ ​ ​ ​ 22.2% ​ ​ Dr. Evangelos (Vangelis) Vergetis(6) ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ Shrikant Sathe(6) ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ Gonzalo Cordova(6) ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ Atanuu Agarrwal(6) ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ Daphne Karydas(6) ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ William Campbell(6) ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ Nina Shapiro(6) ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ Amitabh (Amit) Singhal(6) ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ ​ ​ ​ β€” ​ ​ All directors, director nominees and officers as a group (ten individuals) ​ ​ ​ ​ 2,875,000 ​ ​ ​ ​ ​ 100.0% ​ ​ ​ ​ ​ 2,850,000 ​ ​ ​ ​ ​ 22.2% ​ ​ ​ * Less than one percent ​ (1) Unless otherwise indicated, the business address of each of the individuals is 250 West 55th Street Suite 13D New York, New York 10019. ​ (2) Includes the 350,000 private units to be purchased by our sponsor simultaneously with the consummation of this offering. Assumes (i) no exercise of the over-allotment option and (ii) an aggregate of 375,000 ordinary shares have been forfeited by our sponsor as a result thereof. ​ (3) Based on 2,875,000 ordinary shares immediately prior to this offering. ​ (4) Based on 12,875,000 ordinary shares and 350,000 private units immediately after this offering (assumes (i) the over-allotment option has not been exercised and (ii) an aggregate of 375,000 founder shares have been forfeited by our sponsor as a result thereof). ​ (5) Represents shares held by our sponsor. Each of our officers and directors is expected to become a member of our sponsor. The shares held by our sponsor are beneficially owned by Parag Saxena, our Chief Executive Officer, and Stelios Papadopoulos, our Chairman, the managing members of our sponsor, who have voting and dispositive power over the shares held by our sponsor. ​ (6) Does not include any shares held by our sponsor. This individual is expected to become a member of our sponsor, as described in footnote 5. ​ 111 TABLE OF CONTENTS Immediately after this offering (without the exercise of the underwriters’ over-allotment option), our initial shareholders will beneficially own 20% of the then issued and outstanding ordinary shares (assuming our initial shareholders do not purchase any units in this offering without giving effect to the private placement). Because of this ownership block, our initial shareholders may be able to effectively influence the outcome of all matters requiring approval by our shareholders, including the election of directors, amendments to our memorandum and articles of association and approval of significant corporate transactions. To the extent the underwriters do not exercise the over-allotment option, up to an aggregate of 375,000 founder shares held by our sponsor will be subject to forfeiture. Our sponsor will be required to forfeit only a number of founder shares necessary to maintain our initial shareholders’ 20% ownership interest in our ordinary shares (assuming our initial shareholders do not purchase any units in this offering and without giving effect to the private placement) after giving effect to the offering and without giving effect to the exercise, if any, of the underwriters’ over-allotment option. Subject to certain limited exceptions, our initial shareholders have agreed not to transfer, assign or sell their founder shares until the earlier of (i) one year after the date of the consummation of our initial business combination or (ii) the date on which the closing price of our ordinary shares equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing 150 days after our initial business combination, or earlier, in either case, if, subsequent to our initial business combination, we consummate a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. During the lock-up period, the holders of these shares will not be able to sell or transfer their securities except (1) to any persons (including their affiliates and shareholders) participating in the private placement of the private units, officers, directors, shareholders, employees and members of our sponsor and its affiliates, (2) amongst initial holders or to our officers, directors and employees, (3) if a holder is an entity, as a distribution to its, partners, shareholders or members upon its liquidation, (4) by bona fide gift to a member of the holder’s immediate family or to a trust, the beneficiary of which is a holder or a member of a holder’s immediate family, for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations order, (7) by certain pledges to secure obligations incurred in connection with purchases of our securities, (8) by private sales at prices no greater than the price at which the shares were originally purchased or (9) to us for no value for cancellation in connection with the consummation of our initial business combination, in each case (except for clause 9) where the transferee agrees to the terms of the insider letter. If we are unable to effect a business combination and liquidate, there will be no liquidation distribution with respect to the founder shares. If we are unable to effect a business combination and liquidate, there will be no liquidation distribution with respect to the founder shares. Our sponsor has committed to purchase an aggregate of 350,000 private units at $10.00 per unit. Such purchase will take place on a private placement basis simultaneously with the consummation of this offering. Our sponsor has also agreed that if the over-allotment option is exercised by the underwriters in full or in part, our sponsor will purchase from us at a price of $10.00 per unit the number of private units (up to a maximum of 380,000 private units) that are necessary to maintain in the trust account an amount equal to $10.00 per share sold to the public in this offering. These additional private units will be purchased in a private placement that will occur simultaneously with the purchase of units resulting from the exercise of the over-allotment option. The private units are identical to the units sold in this offering except the private warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees. The holders have agreed (A) to vote their private shares in favor of any proposed business combination, (B) not to propose an amendment to our memorandum and articles of association with respect to our pre-business combination activities prior to the consummation of such a business combination, (C) not to redeem any private shares in connection with a shareholder vote to approve our proposed initial business combination and (D) that such private shares shall not participate in any liquidating distribution upon winding up if a business combination is not consummated, until all of the claims of any redeeming 112 TABLE OF CONTENTS shareholders and creditors are fully satisfied (and then only from funds held outside the trust account). Additionally, the purchasers of the private units have agreed not to transfer, assign or sell any of the private units until after the completion of our initial business combination. Registration Rights Our initial shareholders and their permitted transferees can demand that we register the founder shares, the insider units and underlying securities and any securities issued upon conversion of working capital loans, pursuant to an agreement to be signed prior to or on the date of this prospectus. The holders of the Private Units (or underlying securities) are entitled to demand that the Company register these securities at any time after the Company consummates a Business Combination. In addition, the holders have certain β€œpiggy-back” registration rights on registration statements filed after the Company’s consummation of a Business Combination. 113 TABLE OF CONTENTS​ CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS In August 2020, we issued an aggregate of 2,875,000 founder shares to our initial shareholders for an aggregate purchase price of $25,000, or approximately $0.009 per share. If the underwriters determine the size of the offering should be increased, a share dividend would be effectuated in order to maintain the ownership represented by the founder shares at the same percentage, as was the case before the share dividend. Up to 375,000 founder shares will be subject to forfeiture by our sponsor to the extent the underwriters’ over-allotment option is exercised in full. Subject to certain limited exceptions, our initial shareholders have agreed not to transfer, assign or sell their founder shares until the earlier of (i) one year after the date of the consummation of our initial business combination or (ii) the date on which the closing price of our ordinary shares equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing 150 days after our initial business combination, or earlier, in either case, if, subsequent to our initial business combination, we consummate a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property. Our sponsor has committed to purchase an aggregate of 350,000 (or 380,000 if the over-allotment is exercised in full) insider units in a private placement that will occur simultaneously with the closing of this offering. Our sponsor has agreed not to transfer, assign or sell any of the shares included in the insider units and the respective ordinary shares underlying the warrants included in the insider units until after the completion of our initial business combination. Other than reimbursement of any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations, no compensation or fees of any kind, including finder’s fees, consulting fees or other similar compensation, will be paid to our sponsor, officers or directors, or to any of their respective affiliates, prior to or with respect to our initial business combination (regardless of the type of transaction that it is). Our independent directors will review on a quarterly basis all payments that were made to our sponsor, officers, directors or our or their affiliates and will be responsible for reviewing and approving all related party transactions as defined under Item 404 of Regulation S-K, after reviewing each such transaction for potential conflicts of interests and other improprieties. In addition, in order to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor or our officers and directors may, but are not obligated to, loan us funds as may be required. If we consummate our initial business combination, we would repay such loaned amounts. In the event that the initial business combination does not close, we may use a portion of the offering proceeds held outside the trust account to repay such loaned amounts but no proceeds from our trust account would be used for such repayment. Such loans would be evidenced by promissory notes. The notes would either be paid upon consummation of our initial business combination, without interest, or, at the lender’s discretion, up to $1,500,000 of the notes may be converted upon consummation of our business combination into additional private units at a price of $10.00 per unit (which, for example, would result in the holders being issued 150,000 ordinary shares if $1,500,000 of notes were so converted as well as warrants to purchase 50,000 shares). After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to our shareholders, to the extent then known, in the tender offer or proxy solicitation materials, as applicable, furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of distribution of such tender offer materials or at the time of a shareholder meeting held to consider our initial business combination, as applicable, as it will be up to the directors of the post-combination business to determine executive and director compensation. All ongoing and future transactions between us and any member of our management team or his or her respective affiliates will be on terms believed by us at that time, based upon other similar arrangements known to us, to be no less favorable to us than are available from unaffiliated third parties. It is our intention to obtain estimates from unaffiliated third parties for similar goods or services to ascertain whether such 114 TABLE OF CONTENTS transactions with affiliates are on terms that are no less favorable to us than are otherwise available from such unaffiliated third parties. If a transaction with an affiliated third party were found to be on terms less favorable to us than with an unaffiliated third party, we would not engage in such transaction. We are not prohibited from pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors. In the event we seek to complete our initial business combination with a target that is affiliated with our sponsor, officers or directors, we, or a committee of independent directors, would obtain an opinion from an independent accounting firm, or independent investment banking firm that our initial business combination is fair to our company from a financial point of view. We have entered into a registration rights agreement with respect to the founder shares and insider units, which is described under the heading β€œPrincipal Shareholders — Registration Rights.” 115 T

Holder Stats

1 0
% of Shares Held by All Insider 19.47%
% of Shares Held by Institutions 56.04%
% of Float Held by Institutions 69.58%
Number of Institutions Holding Shares 48

Mutual Fund Holders

Holder Shares Date Reported Value % Out
BlackRock Health Sciences Trust II 897657 2022-03-30 8832944 6.67
First Tr Exchange Traded Fd-First Trust Merger Arbitrage Fd 167525 2022-03-30 1648446 1.24
RiverNorth Opportunities Fd 24174 2022-04-29 238839 0.18
Saba Capital Income & Opportunities Fd 22562 2022-04-29 222912 0.16999999999999998
Price (T.Rowe) Multi Strategy Total Return Fund 9800 2022-04-29 96824 0.07
Fidelity NASDAQ Composite Index Fund 4558 2022-05-30 44987 0.03
CrossingBridge Pre-Merger SPAC ETF 2550 2022-03-30 25092 0.02
iShares BlackRock Future Health ETF 2475 2022-06-29 24502 0.02
First Tr Exchange Traded Fd-First Trust Alternative Opportunities Fd 1410 2022-03-30 13874 0.01
Merger Fund, The 927 2022-03-30 9121 0.01

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2022-08-18 Goldman Sachs Group Inc. 55,622 $550,000 0.0% -90.0% 0.413%
2022-08-17 Centiva Capital LP 140,393 $1,390,000 0.0% +4.9% 1.043%
2022-08-16 Centiva Capital LP 140,393 $1,390,000 0.0% +4.9% 1.043%
2022-08-15 Millennium Management LLC 82,556 $820,000 0.0% -3.0% 0.613%
2022-08-12 Sculptor Capital LP 155,636 $1,540,000 0.0% +103.5% 1.156%
2022-08-12 Hudson Bay Capital Management LP 687,528 $6,810,000 0.1% +34.1% 5.108%
2022-05-20 Sculptor Capital LP 76,493 $750,000 0.0% 0 0.568%
2022-05-17 Radcliffe Capital Management L.P. 102,974 $1,020,000 0.0% +3.0% 0.765%
2022-05-17 Saba Capital Management L.P. 270,751 $2,670,000 0.0% +379.6% 2.012%
2022-05-16 Goldman Sachs Group Inc. 553,622 $5,450,000 0.0% +1,476.7% 4.113%
2022-05-16 Berkley W R Corp 119,047 $1,170,000 0.1% +198.4% 0.885%
2022-05-16 UBS Group AG 2,532 $25,000 0.0% +547.6% 0.019%
2022-05-13 Sculptor Capital LP 76,493 $750,000 0.0% 0 0.568%
2022-05-13 Basso Capital Management L.P. 43,409 $430,000 0.0% +28.4% 0.323%
2022-05-04 Wolverine Asset Management LLC 5,187 $51,000 0.0% -89.7% 0.039%
2022-04-26 Integrity Capital Management HK Ltd 9,755 $96,000 0.5% 0 0.072%
2022-02-18 SkyView Investment Advisors LLC 71,773 $700,000 0.2% +8.0% 0.533%
2022-02-15 Saba Capital Management L.P. 56,451 $550,000 0.0% +110.1% 0.419%
2022-02-14 Deerfield Management Company L.P. Series C 999,999 $9,760,000 0.2% 0 7.430%
2022-02-14 Glazer Capital LLC 66,990 $650,000 0.0% 0 0.498%
2022-02-14 Eisler Capital UK Ltd. 232,600 $2,270,000 0.1% 0 1.728%
2022-02-09 Wolverine Asset Management LLC 50,352 $490,000 0.0% -12.2% 0.374%
2022-01-19 Cantor Fitzgerald Investment Adviser L.P. 74,000 $720,000 0.0% 0 0.550%
2021-11-16 SkyView Investment Advisors LLC 66,463 $650,000 0.2% 0 0.494%
2021-11-16 CNH Partners LLC 85,153 $830,000 0.0% +5.5% 0.633%
2021-11-15 Dark Forest Capital Management LP 10,509 $100,000 0.0% 0 0.078%
2021-11-12 Periscope Capital Inc. 78,498 $770,000 0.0% 0 0.583%
2021-11-12 Wolverine Asset Management LLC 57,356 $560,000 0.0% -8.3% 0.426%
2021-11-12 Magnetar Financial LLC 21,024 $210,000 0.0% +78.2% 0.156%
2021-11-10 Goldman Sachs Group Inc. 37,202 $360,000 0.0% +235.2% 0.276%
2021-11-09 Basso Capital Management L.P. 33,194 $330,000 0.0% 0 0.247%
2021-08-17 Sphera Funds Management LTD. 329,025 $3,240,000 0.2% +8.2% 2.445%
2021-08-17 Price T Rowe Associates Inc. MD 20,300 $200,000 0.0% 0 0.151%
2021-08-16 CNH Partners LLC 80,700 $790,000 0.0% +5.6% 0.600%
2021-08-16 Vivaldi Asset Management LLC 167,425 $1,650,000 0.2% 0 1.244%
2021-08-16 Kingdon Capital Management L.L.C. 200,000 $1,970,000 0.2% 0 1.486%
2021-08-16 Goldman Sachs Group Inc. 11,099 $110,000 0.0% 0 0.082%
2021-08-16 Shay Capital LLC 74,901 $740,000 0.1% -83.4% 0.557%
2021-08-13 Altium Capital Management LP 400,000 $3,940,000 0.9% 0 2.972%
2021-08-11 Arena Capital Advisors LLC CA 100,000 $990,000 0.1% 0 0.743%
2021-08-11 Panagora Asset Management Inc. 9,922 $98,000 0.0% 0 0.074%
2021-08-06 Magnetar Financial LLC 11,800 $120,000 0.0% 0 0.088%
2021-05-18 Rivernorth Capital Management LLC 99,996 $1,000,000 0.1% 0 0.743%
2021-05-18 Jane Street Group LLC 83,552 $830,000 0.0% 0 0.621%
2021-05-17 CNH Partners LLC 76,424 $760,000 0.0% 0 0.568%
2021-05-17 683 Capital Management LLC 600,000 $5,990,000 0.3% 0 4.458%
2021-05-17 EcoR1 Capital LLC 200,000 $2,000,000 0.1% 0 1.486%
2021-05-17 Sphera Funds Management LTD. 304,025 $3,010,000 0.2% 0 2.259%
2021-05-17 Centiva Capital LP 104,707 $1,040,000 0.0% 0 0.778%
2021-05-14 Cowen Investment Management LLC 50,000 $500,000 0.2% 0 0.371%
2021-05-13 Wolverine Asset Management LLC 57,228 $570,000 0.0% +1,807.6% 0.425%
2021-05-12 UBS Group AG 3,954 $39,000 0.0% 0 0.029%
2021-05-12 Granite Point Capital Management L.P. 200,000 $2,000,000 0.1% -47.7% 1.486%
2021-05-07 BlackRock Inc. 925,000 $9,230,000 0.0% 0 6.873%
2021-05-05 Exos Asset Management LLC 10,485 $100,000 0.1% 0 0.078%
2021-05-04 Cowen AND Company LLC 65,296 $650,000 0.0% 0 0.485%
2021-03-04 Hudson Bay Capital Management LP 399,999 $4,019,999 0.0% 0 2.972%
2021-02-16 Radcliffe Capital Management L.P. 100,000 $1,010,000 0.1% 0 0.743%
2021-02-06 Granite Point Capital Management L.P. 382,693 $3,850,000 0.2% 0 2.843%

SEC Filings

Form Type Form Description Filing Date Document Link
PRE 14A PRE 14A 2022-09-28 https://www.sec.gov/Archives/edgar/data/1822929/000110465922103771/tm2226828d1_pre14a.htm
10-Q FORM 10-Q 2022-08-15 https://www.sec.gov/Archives/edgar/data/1822929/000141057822002601/eucr-20220630x10q.htm
10-Q 10-Q 2022-05-23 https://www.sec.gov/Archives/edgar/data/1822929/000141057822001827/eucr-20220331x10q.htm
NT 10-Q NT 10-Q 2022-05-16 https://www.sec.gov/Archives/edgar/data/1822929/000110465922061383/tm2211974-2_nt10q.htm
10-K 10-K 2022-04-11 https://www.sec.gov/Archives/edgar/data/1822929/000141057822000855/eucr-20211231x10k.htm
NT 10-K NT 10-K 2022-03-31 https://www.sec.gov/Archives/edgar/data/1822929/000110465922041148/tm2211139d1_nt10k.htm
SC 13G 2022-02-14 https://www.sec.gov/Archives/edgar/data/1822929/000008025522002250/eucru13gdec21.txt
SC 13G/A 2022-02-08 https://www.sec.gov/Archives/edgar/data/1822929/000083423722008425/vgg3141w1142_020822.txt
8-K FORM 8-K 2022-01-26 https://www.sec.gov/Archives/edgar/data/1822929/000110465922007832/tm224508d1_8k.htm
10-K/A FORM 10-K/A 2021-12-20 https://www.sec.gov/Archives/edgar/data/1822929/000110465921151723/tm2135789d1_10ka.htm
10-Q FORM 10-Q 2021-11-22 https://www.sec.gov/Archives/edgar/data/1822929/000141057821000388/eucr-20210930x10q.htm
8-K FORM 8-K 2021-11-19 https://www.sec.gov/Archives/edgar/data/1822929/000110465921141999/tm2133283d1_8k.htm
NT 10-Q NT 10-Q 2021-11-16 https://www.sec.gov/Archives/edgar/data/1822929/000110465921139436/tm2132982d1_nt10q.htm
10-Q FORM 10-Q 2021-08-16 https://www.sec.gov/Archives/edgar/data/1822929/000110465921106198/eucr-20210630x10q.htm
10-Q FORM 10-Q 2021-07-16 https://www.sec.gov/Archives/edgar/data/1822929/000110465921093067/tm2114127d1_10q.htm
10-K/A FORM 10-K/A 2021-07-15 https://www.sec.gov/Archives/edgar/data/1822929/000110465921092689/tm2119758d1_10ka.htm
8-K FORM 8-K 2021-06-21 https://www.sec.gov/Archives/edgar/data/1822929/000110465921083510/tm2119961d1_8k.htm
8-K FORM 8-K 2021-06-01 https://www.sec.gov/Archives/edgar/data/1822929/000110465921074631/tm2118028d1_8k.htm
NT 10-Q NT 10-Q 2021-05-17 https://www.sec.gov/Archives/edgar/data/1822929/000110465921067378/tm2116578d1_nt10q.htm
10-K FORM 10-K 2021-03-31 https://www.sec.gov/Archives/edgar/data/1822929/000110465921044723/tm214061d1_10k.htm
SC 13G SCHEDULE 13G 2021-02-12 https://www.sec.gov/Archives/edgar/data/1822929/000110465921021890/tm216417d1_sc13g.htm
SC 13G 2021-02-08 https://www.sec.gov/Archives/edgar/data/1822929/000083423721007566/vgg3141w1142_020521.txt
8-K FORM 8-K 2020-12-14 https://www.sec.gov/Archives/edgar/data/1822929/000110465920135338/tm2038469d1_8k.htm
10-Q FORM 10-Q 2020-12-07 https://www.sec.gov/Archives/edgar/data/1822929/000110465920132927/tm2037442d1_10q.htm
8-K FORM 8-K 2020-11-30 https://www.sec.gov/Archives/edgar/data/1822929/000110465920130484/tm2037210d1_8k.htm
4 FORM 4 2020-11-27 https://www.sec.gov/Archives/edgar/data/1822929/000110465920130017/xslF345X03/tm2037212-3_4.xml
4 FORM 4 2020-11-27 https://www.sec.gov/Archives/edgar/data/1822929/000110465920130016/xslF345X03/tm2037212-2_4.xml
4 FORM 4 2020-11-27 https://www.sec.gov/Archives/edgar/data/1822929/000110465920130014/xslF345X03/tm2037212-1_4.xml
8-K FORM 8-K 2020-11-02 https://www.sec.gov/Archives/edgar/data/1822929/000110465920120536/tm2034738d1_8k.htm
SC 13G 2020-10-30 https://www.sec.gov/Archives/edgar/data/1822929/000119380520001340/e620033_sc13g-eba.htm
8-K FORM 8-K 2020-10-28 https://www.sec.gov/Archives/edgar/data/1822929/000110465920118930/tm2034386-1_8k.htm
424B4 424B4 2020-10-26 https://www.sec.gov/Archives/edgar/data/1822929/000110465920118165/tm2029948-10_424b4.htm
EFFECT 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/999999999520002965/xslEFFECTX01/primary_doc.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117619/xslF345X02/tm2034126-11_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117618/xslF345X02/tm2034126-10_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117617/xslF345X02/tm2034126-9_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117616/xslF345X02/tm2034126-8_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117615/xslF345X02/tm2034126-7_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117614/xslF345X02/tm2034126-6_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117613/xslF345X02/tm2034126-5_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117612/xslF345X02/tm2034126-4_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117611/xslF345X02/tm2034126-3_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117610/xslF345X02/tm2034126-2_3.xml
3 FORM 3 2020-10-23 https://www.sec.gov/Archives/edgar/data/1822929/000110465920117609/xslF345X02/tm2034126-1_3.xml
CERT 2020-10-22 https://www.sec.gov/Archives/edgar/data/1822929/000135445720000621/8A_Cert_EUCR.pdf
8-A12B 8-A12B 2020-10-22 https://www.sec.gov/Archives/edgar/data/1822929/000110465920116898/tm2034006d1_8a12b.htm
CORRESP 2020-10-21 https://www.sec.gov/Archives/edgar/data/1822929/000110465920116858/filename1.htm
CORRESP 2020-10-21 https://www.sec.gov/Archives/edgar/data/1822929/000110465920116857/filename1.htm
UPLOAD 2020-10-21 https://www.sec.gov/Archives/edgar/data/1822929/000000000020009941/filename1.pdf
CORRESP 2020-10-21 https://www.sec.gov/Archives/edgar/data/1822929/000110465920116718/filename1.htm
S-1/A S-1/A 2020-10-21 https://www.sec.gov/Archives/edgar/data/1822929/000110465920116715/tm2029948-7_s1a.htm
S-1/A S-1/A 2020-10-15 https://www.sec.gov/Archives/edgar/data/1822929/000110465920115329/tm2029948-5_s1a.htm
S-1 S-1 2020-10-06 https://www.sec.gov/Archives/edgar/data/1822929/000110465920112311/tm2029948-2_s1.htm
CORRESP 2020-10-05 https://www.sec.gov/Archives/edgar/data/1822929/000110465920112312/filename1.htm
UPLOAD 2020-09-29 https://www.sec.gov/Archives/edgar/data/1822929/000000000020009135/filename1.pdf
DRS 2020-09-02 https://www.sec.gov/Archives/edgar/data/1822929/000110465920101557/filename1.htm